NO20033220L - Inhibitorer for cruzipain og andre cysteinproteaser - Google Patents

Inhibitorer for cruzipain og andre cysteinproteaser

Info

Publication number
NO20033220L
NO20033220L NO20033220A NO20033220A NO20033220L NO 20033220 L NO20033220 L NO 20033220L NO 20033220 A NO20033220 A NO 20033220A NO 20033220 A NO20033220 A NO 20033220A NO 20033220 L NO20033220 L NO 20033220L
Authority
NO
Norway
Prior art keywords
inhibitors
cruzipain
cysteine proteases
general formula
compounds
Prior art date
Application number
NO20033220A
Other languages
English (en)
Other versions
NO328208B1 (no
NO20033220D0 (no
Inventor
Martin Quibell
Original Assignee
Amura Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0101179A external-priority patent/GB0101179D0/en
Application filed by Amura Therapeutics Ltd filed Critical Amura Therapeutics Ltd
Publication of NO20033220D0 publication Critical patent/NO20033220D0/no
Publication of NO20033220L publication Critical patent/NO20033220L/no
Publication of NO328208B1 publication Critical patent/NO328208B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20033220A 2001-01-17 2003-07-16 Inhibitorer for cruzipain og andre cysteinproteaser, fremgangsmate for validering av en kjent eller antatt cysteinproteaseinhibitor som et terapeutisk mal, anvendelser av forbindelsene i fremgangsmaten og ved fremstilling av medikamenter, samt farmasoytiske eller veterinaermedisinske preparater og fremgangsmate for fremstilling derav NO328208B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0101179A GB0101179D0 (en) 2001-01-17 2001-01-17 Biologically active compounds
US27535901P 2001-03-13 2001-03-13
PCT/GB2002/000184 WO2002057270A1 (en) 2001-01-17 2002-01-17 Inhibitors of cruzipain and other cysteine proteases

Publications (3)

Publication Number Publication Date
NO20033220D0 NO20033220D0 (no) 2003-07-16
NO20033220L true NO20033220L (no) 2003-09-17
NO328208B1 NO328208B1 (no) 2010-01-11

Family

ID=26245571

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033220A NO328208B1 (no) 2001-01-17 2003-07-16 Inhibitorer for cruzipain og andre cysteinproteaser, fremgangsmate for validering av en kjent eller antatt cysteinproteaseinhibitor som et terapeutisk mal, anvendelser av forbindelsene i fremgangsmaten og ved fremstilling av medikamenter, samt farmasoytiske eller veterinaermedisinske preparater og fremgangsmate for fremstilling derav

Country Status (20)

Country Link
US (2) US7425562B2 (no)
EP (1) EP1362052B1 (no)
JP (1) JP4608183B2 (no)
KR (1) KR100860067B1 (no)
CN (1) CN1269822C (no)
AT (1) ATE356130T1 (no)
AU (1) AU2002219397B2 (no)
BR (1) BR0206501A (no)
CA (1) CA2436462C (no)
CY (1) CY1106640T1 (no)
DE (1) DE60218633T2 (no)
DK (1) DK1362052T3 (no)
ES (1) ES2281516T3 (no)
IL (2) IL156774A0 (no)
MX (1) MXPA03006224A (no)
NO (1) NO328208B1 (no)
NZ (1) NZ526913A (no)
PT (1) PT1362052E (no)
RU (1) RU2329266C2 (no)
WO (1) WO2002057270A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
WO2002051983A2 (en) 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
MXPA04002282A (es) 2001-09-14 2005-03-07 Axis Pharmaceutical Inc Nuevos compuestos y preparaciones como inhibidores de la catepsina.
EP1446392A1 (en) 2001-11-14 2004-08-18 Aventis Pharmaceuticals, Inc. Oligopeptides and compositions containing them as cathepsin s inhibitors
CN100354276C (zh) * 2002-07-16 2007-12-12 阿姆拉医疗有限公司 生物活性化合物
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
SE0400022D0 (sv) * 2004-01-08 2004-01-08 Medivir Ab New compounds
DE602005019971D1 (de) * 2004-01-08 2010-04-29 Medivir Ab Inhibitoren von cysteinprotease
JP2005350417A (ja) * 2004-06-11 2005-12-22 Dai Ichi Seiyaku Co Ltd 還元的エーテル化法を用いたピロリジン誘導体の製造法
PL1865940T3 (pl) * 2005-03-21 2013-06-28 Virobay Inc Alfa-ketoamidowe związki jako inhibitory proteaz cysteinowych
GB0513839D0 (en) * 2005-07-07 2005-08-10 Medivir Ab Cysteine protease inhibitors
GB0513840D0 (en) * 2005-07-07 2005-08-10 Medivir Ab Cysteine protease inhibitors
GB0614037D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614044D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614053D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614052D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614073D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614046D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
WO2008114054A1 (en) * 2007-03-19 2008-09-25 Medivir Ab Protease inhibitors
US7893067B2 (en) * 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
JP5587790B2 (ja) * 2008-01-09 2014-09-10 アミュラ セラピューティクス リミティド 化合物
GB0804702D0 (en) * 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
GB0804701D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
US9409880B2 (en) 2011-01-20 2016-08-09 The Regents Of The University Of Colorado, A Body Corporate Modulators of TLR3/dsRNA complex and uses thereof
CN106963760A (zh) * 2012-08-30 2017-07-21 国立大学法人东京大学 体内寄生虫防治剂在制备防治体内寄生虫的药物中的用途
CN106279188A (zh) * 2016-07-21 2017-01-04 青岛科技大学 一种多取代呋喃并[2,3‑b]吡咯衍生物的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652574A (en) * 1970-04-01 1972-03-28 Abbott Lab Certain 1 2 3 4 - tetrahydro-5h-pyrido (4 3-b)indoles and the corresponding 1 2 3 4-tetrahydro-9h-pyrido(3 4-b)indoles and derivatives thereof
DE3601226A1 (de) * 1986-01-17 1987-07-23 Bayer Ag Dihydropyridinlactole, verfahren zur herstellung und ihre verwendung in arzneimitteln
RU2137768C1 (ru) * 1993-12-15 1999-09-20 Мерк энд Ко, Инк. Ингибиторы hiv протеазы
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
EP0923535A4 (en) 1996-08-28 2001-01-10 Smithkline Beecham Corp CYSTEINE PROTEASE INHIBITORS
ZA9711537B (en) 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
AR013079A1 (es) * 1997-05-06 2000-12-13 Smithkline Beecham Corp Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
MA26618A1 (fr) 1998-04-09 2004-12-20 Smithkline Beecham Corp Composes et compositions pharmaceutiques pour le traitement du paludisme
CO5150165A1 (es) 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
GB9911417D0 (en) * 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
IL155961A0 (en) 2000-11-17 2003-12-23 Medivir Uk Ltd Cysteine protease inhibitors
WO2002051983A2 (en) 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors

Also Published As

Publication number Publication date
CN1269822C (zh) 2006-08-16
KR20030075161A (ko) 2003-09-22
DE60218633T2 (de) 2008-02-21
CY1106640T1 (el) 2012-01-25
WO2002057270A1 (en) 2002-07-25
NO328208B1 (no) 2010-01-11
ES2281516T3 (es) 2007-10-01
US7425562B2 (en) 2008-09-16
DE60218633D1 (de) 2007-04-19
RU2329266C2 (ru) 2008-07-20
ATE356130T1 (de) 2007-03-15
BR0206501A (pt) 2004-01-13
DK1362052T3 (da) 2007-07-09
CA2436462A1 (en) 2002-07-25
RU2003125270A (ru) 2005-02-20
KR100860067B1 (ko) 2008-09-24
EP1362052A1 (en) 2003-11-19
IL156774A (en) 2008-08-07
US20090247471A1 (en) 2009-10-01
EP1362052B1 (en) 2007-03-07
HK1060729A1 (en) 2004-08-20
PT1362052E (pt) 2007-04-30
JP4608183B2 (ja) 2011-01-05
AU2002219397B2 (en) 2008-02-14
NZ526913A (en) 2004-12-24
CN1486320A (zh) 2004-03-31
IL156774A0 (en) 2004-02-08
NO20033220D0 (no) 2003-07-16
MXPA03006224A (es) 2004-10-15
CA2436462C (en) 2011-07-05
JP2004518674A (ja) 2004-06-24
US20040138250A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
NO20033220D0 (no) Inhibitorer for cruzipain og andre cysteinproteaser
SE0201976D0 (sv) Novel compounds
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
TR200100605T2 (tr) Arilpiperazinler ve bunların metaloproteinaz inhibe edici maddeler (MMP) olarak kullanımı
ATE368034T1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
SE0102315D0 (sv) Compounds
ATE445400T1 (de) Hydantion-derivate als hemmer von matrix- metalloproteinasen
BR0111451A (pt) Inibidores de serina protease
CO5210911A1 (es) Trifluorbutenos nematicidas
EA200301100A1 (ru) Новые фталазиноны
CY1108446T1 (el) Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αντιμετωπιση αποπληξιας
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
DE60105418D1 (de) Serinprotease-inhibitoren
ATE355101T1 (de) Inhibitoren von serin proteasen
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
ATE349448T1 (de) Pyrazol-3,4-d-pyrimidinderivate und ihre verwendung bei der behandlung von h.pylori- infektionen
DK1379508T3 (da) N-(aryl)-2arylethensulfonamider og terapeutiske anvendelser deraf
SE0003476D0 (sv) Compounds
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
DE60033809D1 (de) Inhibitoren von metalloproteinasen
DK1377574T3 (da) 6-phenylbenzonaphtyridiner
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
DK1558580T3 (da) N-sulfonyl-4-methylenamino-3-hydroxy-2-pyridoner
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees